🇺🇸

US SEC Filing Intelligence

· daily

US Material Events SEC 8-K Filings — March 10, 2026

Across 50 SEC filings from March 10, 2026, overarching themes include widespread C-suite transitions (12+ neutral departures/appointments in healthcare, tech, energy), a financing surge with $5B+ in debt/equity raises (e.g., Applied Digital $2.15B notes, AN2 $40M PP), 15+ debt refinancings/expansions enhancing liquidity, one high-profile bankruptcy confirmation, and asset sales/debt paydowns reducing leverage. Period-over-period trends reveal robust revenue growth in consumer staples (Westrock +39.8% FY2025 YoY sales, Nature’s Sunshine +5.7% FY2025) but mixed EBITDA (Walker & Dunlop -4% YoY to $316M, Westrock Q4 +2.3% gross profit) and frequent margin compression from scale-up costs/investments. Forward-looking signals are optimistic with Westrock 2026 Adj EBITDA guidance $90-100M (+29-44% YoY), Nature’s $500-515M sales (+4-7%), and Walker’s '30 targets ($80B+ originations). No insider trading patterns noted, but capital allocation favors debt reduction (Ashford $95M sale pays $94.7M mortgage) over dividends/buybacks. Portfolio-level: Biotech/energy lead positive catalysts via PP/deals; executive churn signals potential volatility; relative outperformance in refinancings vs deteriorating ops in isolated cases like Nine Energy bankruptcy.

50 high priority 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 10, 2026

Across the 7 S&P 500 Technology stream filings dated March 10, 2026, key themes include robust cloud and AI-driven growth in established tech leaders like Oracle (+22% YoY total revenue, +44% cloud), contrasted with declines in peripheral holdings like CMCT (-6.3% YoY revenue, net loss widened 53.7%), and progress in quantum tech M&A via dMY Squared's business combination. Period-over-period trends show Oracle as a standout outlier with RPO surging 325% YoY to $553B and raised Q4 FY26 guidance (total revenue +19-21%, cloud +46-50%), while CMCT exhibits segment-wide weakness (office -7.6%, multifamily -19.1%). Proxy filings from IBM (positive sentiment on AI/hybrid cloud) and others signal governance focus and upcoming AGMs, with no insider trading activity reported across filings but capital allocation highlights like Oracle's $0.50 dividend and $30B bond raise. Portfolio-level patterns reveal tech core strength (2/7 filings with strong growth) amid mixed sentiment (3 mixed, 2 positive), implying bullish rotation into cloud/AI plays. Critical developments like dMY's PIPE ($111.9M) and registration effectiveness point to M&A catalysts, while scheduled events create near-term volatility opportunities.

4 high priority 3 medium 7 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 10, 2026

Across the four NASDAQ-100 stream filings dated March 10, 2026, overarching themes include revenue pressures in real estate and coffee segments contrasted by resource expansion and M&A catalysts. CMCT reported 6.3% YoY revenue decline to $116.7M with net loss widening 53.7% to $39.6M due to segment declines and impairments, while KDP Coffee saw flat 1% YoY sales growth to $4.7B, net income down 5% to $700M, but OCF surged 37% to $629M ahead of Q2 2026 spin-off. LBSR aggressively expanded with 13 new claims adding 11.18 sq mi (total footprint +55% to 31.49 sq mi) in Arizona's copper belt, signaling critical minerals upside. Putnam's DEF 14A is routine governance with April 17 AGM. Portfolio trends show mixed sentiment (2/4 mixed, 1 positive, 1 neutral), average materiality 7.5/10, with asset declines at CMCT (-3.4% to $859.2M) vs capex growth at KDP (PPE +9% to $944M). Implications: Avoid overexposed REITs amid margin squeezes, favor mining explorers and M&A plays for alpha amid softening revenues averaging -2.6% YoY where declining.

3 high priority 1 medium 4 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 10, 2026

Across 50 SEC filings from March 10, 2026, primarily non-DJ30 but blue-chip adjacent names show mixed performance with robust revenue growth in defense/security (e.g., Cadre +7.6% YoY sales, AeroVironment +143% Q3) and education retail (Barnes & Noble +11.3% Q3), offset by declines in retail (Kohl's -4% FY), chemicals (Valhi FY loss $57.6M vs profit), and biotechs (Artiva loss +28% YoY). Period-over-period trends reveal 12/20 earnings reporters with YoY revenue growth averaging +25% (outliers Aero +143%, Evolv +40%), but margin compression in 8/15 (avg -100bps, e.g., Aero 38% to 24%) and net losses widening in 10/20 (avg +50%). M&A activity surges with 5 approvals/deals (Alexander & Baldwin 99% vote, York Space shares issued), while banks emphasize governance (M&T CET1 10.84%, US Bancorp new Tech Committee). Forward guidance optimistic in growth names (Cadre +22% 2026 sales), but risks from regulatory (Elevance CMS sanctions Mar 31) and distress (Nine Energy bankruptcy confirmed). Capital allocation favors dividends (Cadre +5.3%, Kohl's $0.125) over buybacks; proxy season ramps with 10+ AGMs in April. Portfolio implication: overweight defense/M&A plays, underweight cyclicals amid mixed sentiment (22 mixed, 10 positive).

19 high priority 31 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — March 10, 2026

Across 50 SEC filings for March 10, 2026, dominant themes include widespread equity dilution from ATM offerings, private placements, and shelf registrations (e.g., Trio Petroleum $17.4M sold/18.1M shares, Aclaris $39.8M/12.7M shares, AN2 $40M), signaling capital needs amid mixed FY25 results with average revenue growth of ~10% YoY in reporting companies (TWFG +22%, Arq +10%, Custom Truck +7.9%) but frequent net loss widening (Bullish -$785M vs +$80M, Arq -$52.6M vs -$5.1M, Trailblazer -$8.3M vs +$0.28M) driven by impairments and fair value hits. Healthcare firms reaffirmed FY26 guidance despite regulatory headwinds (Elevance $25.50+ EPS amid CMS sanctions effective March 31, Centene >$3.00 adj EPS), while SPAC/de-SPAC activity surged with amendments facilitating deals (IQM/RAAQ $1.8B value, Horizon Quantum PIPE $111.9M). Energy/mining showed operational challenges (URANIUM sales -59% YoY, Arq pausing GAC production) offset by balance sheet strengthening via raises, and REITs/RE faced revenue declines (Creative Media -6.3%, ACRES NII -19%). Capital allocation leaned toward buybacks (News Corp $1B program) and debt raises (Duke $1.3B notes), with M&A catalysts imminent (Alexander & Baldwin merger ~March 12). Portfolio-level trends highlight margin compression averaging -150bps in 6/10 industrials/energy (Arq -830bps gross), but improving EBITDA in select names (UNFI +23.4%, TWFG +47%). Implications favor monitoring biotech catalysts and SPAC closes for alpha, while dilution risks weigh on small caps.

23 high priority 27 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 10, 2026

Across 44 SEC filings from the S&P 500 Consumer Discretionary stream (broadly including retail, distribution, leisure, and adjacent financials), mixed sentiment prevails with 70% of financial reporters showing 'mixed' ratings, reflecting revenue growth in high-performers (avg +25% YoY in WLFC 28%, Westrock 40%, TWFG 22%) offset by sales declines in distributors (UNFI -2.6% YoY Q2/Q3). Margin trends diverge: EBITDA expansions (UNFI +23% Q2, WLFC Adj EBITDA +17%) amid op ex cuts, but gross margin compressions (Westrock -560bps to 12.7%, Ultralife impairments) signal scaling costs. Critical developments include M&A (York-Orbion merger, Ashford $95M hotel sale/debt paydown, Infinity Antero acquisition), exec changes (Xponential/SolarEdge CFO departures, Prudential CEO-to-Chairman), and resilient guidance (UNFI raises FY26 EBITDA to $680-710M despite sales cut; Westrock 2026 EBITDA $90-100M +29-44%). Portfolio-level patterns show capital allocation prioritizing debt reduction (Ashford -2.6% indebtedness, UNFI net leverage to 2.3x) and shareholder returns (Enbridge 3% div hike, 31st year; CCEP share repurchases). Consumer spending softness in retail/food distribution contrasts leasing/production strength, implying selective opportunities in growth niches amid macro caution.

26 high priority 18 medium 44 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 10, 2026

Across 33 filings in the USA S&P 500 Healthcare intelligence stream (with extraneous cross-sector inclusions), healthcare firms show mixed performance: managed care leaders like Elevance Health and Centene reaffirmed FY2026 EPS guidance ($25.50+ and >$3.00 adj) despite regulatory headwinds, while biotechs like Lipocine (-82% YoY revenue to $2.0M), Medicinova (+8.6% net loss to $12.0M), and Skye Bioscience (+110% net loss to $55.9M) highlight R&D burn and pipeline risks. Period-over-period trends reveal revenue declines averaging -25% YoY in reporting biotechs/pharma (e.g., Lipocine -82%, CVG proxy -10.3% but non-health), offset by positive trial data (Citius 24% ORR) and leadership stability. No widespread insider trading activity noted, but capital allocation leans defensive with Centene's $1B note redemption and News Corp/Coke buybacks (non-core). Forward-looking catalysts cluster in Q2 2026 (Lipocine NDA, Skye Phase 2b). Portfolio-level: 7/12 core healthcare filings mixed sentiment, margin compression in ops-heavy (e.g., ACRES NII -19% YoY), signaling caution amid regulatory (CMS sanctions March 31) and clinical risks, but opportunities in undervalued pipelines.

19 high priority 14 medium 33 total filings
· daily

Global High-Priority Regulatory Events — March 10, 2026

Across 50 filings centered on global high-priority events like insolvencies, SPACs, IPOs, and M&A, a dominant theme is financial distress in Indian infrastructure firms (e.g., Morarjee Textiles, VAS Infrastructure, Setubandhan) with ongoing CIRP and NCLT hearings signaling prolonged uncertainty. Biotech and SPAC sectors show mixed results: revenues grew in select cases like TWFG (+22% YoY) and Custom Truck (+7.9% YoY), but net losses widened sharply in biotechs (e.g., Cullinan +31% YoY, Rapport +42% YoY) due to R&D surges amid clinical investments. Period-over-period trends reveal revenue growth averaging +10-20% in resilient sectors like insurance (TWFG) and rentals (Custom Truck), contrasted by asset impairments and sales declines in energy/mining (Arq net loss to $52.6M, Uranium sales -59% YoY). Positive catalysts include SPAC mergers (IQM/RAAQ at $1.8B valuation, Horizon Quantum PIPE amendments) and strategic deals (Atlas Energy $840M Caterpillar pact), while insolvencies cluster around March 20 NCLT decisions. Capital allocation leans toward dilutions (e.g., Guided Therapeutics +5.6%) and cash raises over buybacks/dividends, with no major insider buys but executive changes (e.g., Playtika CFO resignation). Overall, portfolio-level patterns favor monitoring turnaround plays in SPACs/energy amid broad margin pressures (e.g., ACRES yield -150bps YoY). Actionable now: Avoid Indian insolvency names; eye SPAC closes and biotech cash runways.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 10, 2026

The IPO Pipeline stream features a single high-materiality S-1 filing from Pershing Square Capital Management (PSCM) on March 10, 2026, signaling an imminent IPO via its flagship NYSE-listed vehicle PSUS, focused on minority stakes in high-quality growth companies. Key developments include the completed Howard Hughes Transaction on May 5, 2025, which transformed HHH into a diversified holding company, and the $2.1B Vantage Acquisition announced December 17, 2025, slated for Q2 2026 close, enhancing portfolio scale amid a $3.75M quarterly HHH Base Management Fee structure. Positive sentiment dominates with emphasis on long-term value creation and synergies, though risks like concentrated exposure are noted; no explicit period-over-period financial trends are detailed in the filing referencing Q/E September 30, 2025. This filing underscores a bullish resurgence in investment management IPOs, positioning PSCM as a portfolio-level outlier in concentrated activist strategies. Market implications include potential pre-IPO hype and post-listing catalysts from deal integrations, with no cross-filing comparisons available due to single entry.

1 high priority 1 total filings
· daily

US Earnings Financial Results SEC Filings — March 10, 2026

Across 50 US SEC filings for Q4 2025 and FY2025 earnings, overarching themes include mixed financial performance with 28/50 companies showing revenue growth (avg +12% YoY where reported) offset by widespread operating losses and margin compression (avg -150bps in 15/22 detailed cases), particularly in biotechs and cyclicals. Biotech firms (e.g., Q32 Bio, Rapport) reported collaboration revenue boosts but R&D surges widening losses 20-50% YoY, while service/revenue growers like TWFG (+22% rev, +44% NI) and Evolv (+40% rev, EBITDA positive swing) stood out. SPACs faced heavy redemptions and trust declines (Trailblazer assets -84%), energy/mining mixed (Uranium Energy profit swing), and real estate/REITs saw portfolio contractions. Capital allocation leaned toward financing raises over buybacks/dividends (only 4 cases), with cash burn persistent in 22/50 but improving FCF in 10. Portfolio-level: Net losses in 32/50, but 18 showed loss narrowing or profit swings; implications point to selective opportunities in high-growth niches amid macro caution, with no major guidance changes but risks from impairments/delisting.

50 high priority 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 10, 2026

A wave of 18 DEF 14A proxy statements filed around March 10, 2026, primarily for virtual annual meetings in late April to early May 2026, highlights robust governance practices across US companies, with universal emphasis on director elections (avg board size 10-13, reductions in USB from 13 to 12 and Roadzen from 7 to 6), advisory say-on-pay votes, and auditor ratifications. Period-over-period trends show pockets of strength (M&T top-quartile 3.67% NIM FY2025, Chemours 56% YoY Opteon sales growth) amid mixed results (Chemours flat $5.8B sales YoY, -3% Adjusted EBITDA to $742M, net loss widened to $386M on $270M+ litigation). Banking sector leads with positive sentiment (USB, M&T) and new Tech/Cyber committees (effective Jan 1, 2026), signaling proactive risk management; tech/industrials emphasize board refreshment (e.g., IBM Ramon Laguarta addition, Whirlpool 5 new independents in 5 years). No widespread insider selling noted, but capital returns persist (Chemours $78M dividends). Portfolio implications: Governance enhancements support long-term stability, but litigation drags (Chemours) and neutral pay-vs-performance disclosures warrant monitoring say-on-pay outcomes for comp alignment risks.

18 high priority 18 total filings
· daily

US Executive Officer Management Changes SEC — March 10, 2026

Across 34 filings in the USA Executive & Director Changes stream (19 new), the dominant theme is board and C-suite transitions, with 15 appointments/promotions (e.g., experienced CFOs at Equinix, Procore) signaling strategic strengthening, 14 neutral resignations/retirements (no disagreements noted), and 5 key CFO departures (Playtika, Xponential, SolarEdge) amid interim placements. Where financial enriched data is available (8/34 filings), revenue trends are robust—avg +37% YoY across Westrock Coffee (+39.8%), Shoulder Innovations (+50%), Virtuix (+41% 9m), Nature's Sunshine (+5.7%)—but margins mixed with compressions (Westrock gross -2%, Shoulder 76.5% vs 77%) and loss widening due to SG&A/R&D investments. Positive forward-looking signals include reaffirmed guidance (Procore FY26, SolarEdge Q1, Xponential FY26) and upbeat outlooks (Westrock 2026 EBITDA +29-44%, Nature's FY26 sales +4-7%). No insider trading patterns, but capital allocation favors retention via salary hikes (Citizens CEO +20%, Cross Country CAO to $340k) and RSU grants. Portfolio implication: Bullish for firms hiring top talent amid growth; monitor CFO churn in high-growth sectors for execution risks. Overall sentiment leans neutral-positive (18 positive/mixed, 14 neutral/negative), with healthcare/tech leading hires.

34 high priority 34 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — March 10, 2026

Across 45 filings in the USA Corporate Distress & Bankruptcy stream, key themes include widespread dilutive equity raises (12+ companies, e.g., AN2 $40M at $2.85/share ~20% dilution potential, US Energy $8.2M), debt refinancings/extensions (15+ firms like AECOM $2.95B facilities, Hallador $120M to 2029), and Nasdaq delisting risks/reverse splits (5 cases: SolarMax, OSR Holdings, ClearSign 1:10, Origin 1:30, PMGC 6:1) signaling microcap distress. One outright bankruptcy confirmation (Nine Energy prepackaged plan in 33 days). Period-over-period trends mixed: EBITDA -4% YoY at Walker & Dunlop to $316M amid volume drops; KDP Coffee sales +1% YoY to $4.7B but net income -5% YoY to $700M, OCF +37% YoY to $629M; BlackLine margins +6% over 2 years with 2026 revenue guide 9.1-9.6%. Larger caps show capital access strength (Eaton $8.5B notes, FIS $6.8B), while biotechs/energy services cluster distress signals. Portfolio implications: Distress confined to small caps (low participation warrant exchanges like Guided 22.7%), potential alpha in post-reorg plays but contagion risk from Nasdaq failures.

45 high priority 45 total filings
· daily

US SEC Trading Suspension Halt Orders — March 10, 2026

Both SolarMax Technology and OSR Holdings received Nasdaq deficiency notices under Rule 5550(a)(2) for failing the $1 minimum bid price requirement, highlighting acute delisting risks in the USA Trading Suspensions stream. SolarMax was notified on March 3, 2026, with a 180-day compliance window ending August 31, 2026, while OSR received an additional 180-day extension on March 5, 2026, after its initial period expired on March 4, 2026, signaling prolonged stock price weakness. No period-over-period financial trends, insider activity, capital allocation details, or operational metrics were disclosed in the filings, focusing solely on regulatory non-compliance. 2/2 companies (100%) exhibit negative sentiment (materiality 9/10), with identical compliance deadlines creating a synchronized delisting catalyst. This portfolio-level pattern underscores microcap vulnerability to Nasdaq standards, implying broad bearish pressure on low-priced stocks absent rapid price recovery. Immediate delisting triggers (bid <=$0.10 for 10 days) amplify downside risks, urging investors to monitor bid prices closely.

2 high priority 2 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — March 10, 2026

The USA Bankruptcy & Insolvency stream features one key filing from Nine Energy Service, Inc., confirming its Amended Joint Prepackaged Chapter 11 Plan of Reorganization on March 4, 2026, just 33 days after petitioning on February 1, 2026, in the U.S. Bankruptcy Court for the Southern District of Texas (Case No. 26-90295). This rapid prepackaged process, backed by an RSA with over 70% of Senior Secured Notes holders and 100% of Prepetition ABL Claims holders, and completed with no unresolved objections, underscores acute debt distress in the energy services sector but demonstrates strong creditor alignment for a swift emergence. No period-over-period financial metrics, forward-looking guidance, insider trading activity, capital allocation details, or operational metrics were disclosed, limiting quantitative trend analysis but amplifying the negative sentiment (rated negative, materiality 10/10). Market implications include likely dilution or cancellation of existing equity, potential trading halts or delistings, and a cleaner balance sheet post-reorg as a portfolio-level signal of ongoing insolvency pressures in cyclical energy subsectors. This isolated event highlights broader themes of creditor-driven restructurings amid commodity volatility, with no cross-filing comparisons available due to n=1.

1 high priority 1 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 10, 2026

Across 34 US SEC filings on board and executive changes dated March 10, 2026, a dominant theme is high turnover in C-suite finance roles, with 9 CFO/CAO/CRO resignations or transitions (e.g., Playtika, NextEra, Xponential, SolarEdge, Equinix) and 7 new appointments (e.g., Harvard Bioscience, Procore, Equinix), signaling potential strategic shifts amid sector pressures. Where financial enriched data is available (7 filings), revenue growth averages +37% YoY (Westrock +39.8%, Shoulder Innovations +50%, Virtuix +41% 9mths, Nature's Sunshine +5.7%), but profitability is mixed with net losses widening in 3/4 cases (Westrock net loss $90.4M vs $80.3M, Shoulder FY loss $40.4M vs $15.6M) and gross margins stable/slightly down (-20bps avg). Positive sentiments prevail in 10/34 filings (29%), driven by experienced hires like Equinix's Olivier Leonetti (30+ yrs exp) and ADM's Michael McMurray, while neutrals dominate resignations (no disagreements noted in 15 cases). Forward-looking guidance in 5 firms shows optimism (Westrock EBITDA +29-44%, Nature's sales +4-7%, Shoulder +31-37%), but CFO searches create near-term uncertainty. Portfolio implications include monitoring finance-heavy sectors (REITs, tech, energy) for execution risks, with board additions enhancing governance in growth firms.

34 high priority 34 total filings
· daily

US Merger & Acquisition SEC Filings — March 10, 2026

The 12 filings highlight intense SPAC activity (7/12 filings) focused on lifecycle management including over-allotments, trust extensions, unit separations, and de-SPAC progress, signaling sustained M&A pursuit amid avoiding liquidations. Ashford Hospitality's $95.3M hotel sale enabled $94.7M debt reduction, improving pro forma equity deficit by 15% to $453M from $533M (as of Sep 30, 2025), though 2024 revenue dipped 2% YoY to $1.15B with mixed net loss trends (94% improvement in 2024 to $5.3M but slight 9M2025 worsening to $137.6M). Governance shifts and dilutions dominate non-SPAC filings, with Klotho authorizing 50k Series C preferred convertible to 2.13B common shares post-approval, and Strategic Acquisitions issuing 40M shares boosting insider ownership to 86% via dilution. Forward-looking catalysts include SPAC combination deadlines (e.g., byNordic to Apr 12, 2026) and merger filings (Lake Superior F-4 upcoming), while Eventbrite's share authorization slash to 100 signals imminent going-private or merger. No broad portfolio revenue growth (only Ashford data shows -2% YoY), but capital allocation leans to debt reduction and extensions; neutral/mixed sentiment prevails (9/12), with SPACs showing positive procedural wins. Implications: M&A pipelines active but dilution risks high for microcaps, favoring selective SPAC plays with extensions.

12 high priority 12 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 10, 2026

Overnight SEC filings reveal a diverse mix of 50 reports dominated by biotech and energy sector financings (e.g., Aclaris $39.8M, AN2 $40M), SPAC/M&A advancements (e.g., Alexander & Baldwin merger approved, IQM-RAAQ), and healthcare guidance reaffirmations amid risks (Elevance, Centene). Period-over-period trends show revenue growth in select areas like TWFG (+22% YoY), Custom Truck (+7.9% YoY), Arq (+10% YoY), but widespread margin compression (Arq gross margin -830 bps YoY, ACRES yield -155 bps), impairments (Arq $45M, Trailblazer assets -84% YoY), and losses widening (Bullish $785M net loss, BioNTech operating loss deepened). Capital allocation leans toward dilutions via ATMs/private placements (Trio $17.4M sold, 10+ shelf/S-1/F-1 filings) and buybacks (News Corp $1B program), with insider/activist activity limited but notable (Lululemon 13D/A nominations). Forward-looking catalysts cluster in Q2 2026 (Pershing Vantage close, Lipocine topline April), signaling portfolio-level caution on dilution-heavy small-caps versus stability in large-cap healthcare/insurance. Sector themes highlight biotech resilience via milestones despite cash burns, SPAC amendments easing paths to close, and industrial turnarounds via guidance (Arq FY26 $120-125M rev). Actionable now: Favor guidance-steady names, monitor merger votes.

24 high priority 26 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 09, 2026

Across the 50 filings in the USA S&P 500 Consumer Staples intelligence stream (though spanning diverse sectors including logistics, biotech, SPACs, and select staples-adjacent like Kronos TiO2 for coatings/paper), sentiment is predominantly mixed (12/50), with revenue growth in 7/12 reporting companies averaging +24% YoY (e.g., FuelCell +61%, Myomo +26%, Amex GBT +12% FY) offset by widespread margin compression averaging -143 bps (e.g., Amex GBT -243 bps Q4, Myomo -550 bps FY) and impairments/losses (Kronos FY loss swing, ULH $124M impairment). Period-over-period trends reveal top-line resilience in services/biotech amid cost pressures, with 5/8 companies showing gross margin declines despite volume/AUR gains (Signet SSS +1.2% FY but promotions hit margins). Capital allocation leans shareholder-friendly with $100M+ buybacks (Kimbell, Amex GBT doubled to $600M) and steady dividends (Ellington $0.08/share), while financings exceed $500M (Korro $85M PIPE, OPAL $180M). Insider activity is sparse but stable (lululemon activist holds 8.4%), no major sells flagged. Forward-looking catalysts cluster in Q1-Q2 2026 (Myomo rev guidance $43-46M, annual meetings April, Relmada Phase 3 mid-2026), signaling near-term volatility but growth potential in resilient segments. Portfolio implication: Favor cos with strong guidance/backlogs (Korn Ferry +11% remaining fees) over impairment-heavy names (ULH, Kronos).

25 high priority 25 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 09, 2026

Across the 50 filings in the USA S&P 500 Industrials intelligence stream (despite heavy biotech/pharma overlap), overarching themes include robust revenue growth in select industrials and biotechs (avg +18% YoY across 20+ with data) offset by widespread net loss expansion (avg +60% YoY in 15 cos) due to surging R&D/SG&A expenses (up 50-200% in multiple cases). Period-over-period trends show margin compression in 8/15 reporting cos (avg -150bps), but strong backlogs (+33% YoY Voyager), guidance raises (Voyager +35-53%), and capital raises extending runways to 2028 in 7 cos. Critical developments: Defense/space growth (Voyager Q4 sales +24% YoY), construction outperformance (GLDD rev +16.5%, NI +28.4%), frequent M&A/acquisitions (5 in Voyager), and dense 2026 catalysts (FDA updates, trial data). Portfolio-level patterns reveal biotech-heavy mix with industrials shining on ops metrics; capital allocation favors raises/dividends over buybacks. Market implications: Tactical buys in guided growth names, caution on loss-makers amid high burn; alpha from catalysts in H1-H2 2026.

29 high priority 21 medium 50 total filings